NYSE
According to Zyberno, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is not a buy — WEAK BUSINESS (32/100) with a negative Margin of Safety of -14.1% and a Brina Gap of -36.1% showing the market already prices in more growth than the fundamentals support.
According to Zyberno's DCF model, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) trades at $291.50 against an estimated intrinsic value per share of $255.39 — a -14.1% Margin of Safety based on Owner Earnings of $401.96M TTM, projected at 19.6% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -36.1% weakens the case: based on the company's ROIC (2.4%) and reinvestment rate (-139.0%), the business can fundamentally grow at -3.4% — but the current enterprise value implies the market expects 32.7%. This places CRL in the Expensive Hype quadrant of the Brina Matrix, the most fragile combination — overvalued on cash AND overpriced on growth. Zyberno's model translates this into a 5-year expected return of 16.4% annually.
Over the trailing twelve months, CRL generated $401.96M in Owner Earnings. Capital was deployed as follows: $208.29M returned via share buybacks, $215.74M invested in capital expenditures. Reinvestment rate: -139.0%. Owner Earnings have grown at 19.6% annually over the trailing five years using log-linear regression.